Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas - Annals of Oncology
Metronomic Chemotherapy - Ethos Veterinary Health
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts | Oncogene
Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity - Annals of Oncology
Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T... | Oncotarget
IJMS | Free Full-Text | Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway | HTML
Metronomic oral cyclophosphamide in relapsed ovarian cancer | International Journal of Gynecologic Cancer
Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center - Lu - 2020 - Cancer Communications - Wiley Online Library
Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate | British Journal of Cancer
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?: Trends in Cancer
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study | BMC Cancer | Full Text
Metronomic chemotherapy in breast cancer | Semantic Scholar
Metronomic cyclophosphamide and methotrexate for breast cancer: Enhanced efficacy by adding dalteparin and low-dose prednisone? - The Breast
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
Oral Metronomic Cyclophosphamide with and without Methotrexate as Palliative Treatment for Patients with Metastatic Breast Carcinoma | Anticancer Research
Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM) -
Metronomic chemotherapy of thalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients - Clinical Lymphoma, Myeloma and Leukemia
A) Single low-dose cyclophosphamide is superior to metronomic... | Download Scientific Diagram
Unexpected benefit from an 'old' metronomic chemotherapy regimen in advanced chordoma | BMJ Case Reports
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer | npj Breast Cancer
Metronomic cyclophosphamide: An alternative treatment for hepatic epithelioid hemangioendothelioma - Journal of Hepatology
Metronomic Cyclophosphamide with Cisplatin and Bevacizumab: A New Chemotherapeutic Regimen for Refractory Anaplastic Ependymoma | Anticancer Research
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer - Gynecologic Oncology
Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical
Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives - Cancer Treatment Reviews
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | SpringerLink
